Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Liabilities (2016 - 2025)

Seres Therapeutics' Total Liabilities history spans 11 years, with the latest figure at $99.8 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 35.55% year-over-year to $99.8 million; the TTM value through Sep 2025 reached $99.8 million, down 35.55%, while the annual FY2024 figure was $126.0 million, 68.76% down from the prior year.
  • Total Liabilities for Q3 2025 was $99.8 million at Seres Therapeutics, down from $110.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $408.8 million in Q2 2024 and bottomed at $99.8 million in Q3 2025.
  • The 5-year median for Total Liabilities is $238.9 million (2022), against an average of $249.9 million.
  • The largest annual shift saw Total Liabilities soared 56.71% in 2023 before it crashed 72.88% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $223.4 million in 2021, then skyrocketed by 51.33% to $338.0 million in 2022, then rose by 19.37% to $403.5 million in 2023, then crashed by 68.76% to $126.0 million in 2024, then decreased by 20.83% to $99.8 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Total Liabilities are $99.8 million (Q3 2025), $110.8 million (Q2 2025), and $113.7 million (Q1 2025).